StockData
Biomerica Inc logo

Biomerica Inc (BMRA) stock

BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026Score 8/3049% below fair value
$1.24−0.08 (-6.44%)

Close on Nov 17, 2026Market cap $5.68MP/E –Yield –

Biomerica r&d expenses

Research and development expenses are spending on new products and technology.

Biomerica's R&D Expenses for the twelve months ending Aug 31, 2026 was $782.00K, down 16.6% year over year. For fiscal 2026 it was $788.00K, down 23.0% from the year before. Over ten years it grew 0.1% a year on average. The highest annual figure on record is $2.19M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026May 31, 2026$788.00K-23.0%
FY2025May 31, 2025$1.02M-31.4%
FY2024May 31, 2024$1.49M-5.9%
FY2023May 31, 2023$1.58M-12.6%
FY2022May 31, 2022$1.81M-17.4%
FY2021May 31, 2021$2.19M+13.6%
FY2020May 31, 2020$1.93M+15.1%
FY2019May 31, 2019$1.68M+20.1%
FY2018May 31, 2018$1.40M+23.7%
FY2017May 31, 2017$1.13M+44.9%
FY2016May 31, 2016$780.33K+6.4%
FY2015May 31, 2015$733.64K+24.4%
FY2014May 31, 2014$589.87K+28.5%
FY2013May 31, 2013$459.09K+32.3%
FY2012May 31, 2012$347.13K-17.5%
FY2011May 31, 2011$420.57K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ3 2026Aug 31, 2026$206.00K-2.8%
Q4 FY2026CQ2 2026May 31, 2026$205.00K-18.7%
Q3 FY2026CQ1 2026Feb 28, 2026$178.00K-18.0%
Q2 FY2026CQ4 2025Nov 30, 2025$193.00K-24.9%
Q1 FY2026CQ3 2025Aug 31, 2025$212.00K-28.6%
Q4 FY2025CQ2 2025May 31, 2025$252.00K-4.9%
Q3 FY2025CQ1 2025Feb 28, 2025$217.00K-36.7%
Q2 FY2025CQ4 2024Nov 30, 2024$257.00K-37.6%
Q1 FY2025CQ3 2024Aug 31, 2024$297.00K-37.1%
Q4 FY2024CQ2 2024May 31, 2024$265.00K-28.2%
Q3 FY2024CQ1 2024Feb 29, 2024$343.00K-12.5%
Q2 FY2024CQ4 2023Nov 30, 2023$412.00K-10.8%
Q1 FY2024CQ3 2023Aug 31, 2023$472.00K+30.7%
Q4 FY2023CQ2 2023May 31, 2023$369.00K-25.5%
Q3 FY2023CQ1 2023Feb 28, 2023$392.00K+1.3%
Q2 FY2023CQ4 2022Nov 30, 2022$462.00K-15.7%
Q1 FY2023CQ3 2022Aug 31, 2022$361.00K-5.4%
Q4 FY2022CQ2 2022May 31, 2022$495.42K+63.8%
Q3 FY2022CQ1 2022Feb 28, 2022$387.10K-31.4%
Q2 FY2022CQ4 2021Nov 30, 2021$547.93K-11.1%
Q1 FY2022CQ3 2021Aug 31, 2021$381.54K-46.4%
Q4 FY2021CQ2 2021May 31, 2021$302.43K-55.8%
Q3 FY2021CQ1 2021Feb 28, 2021$563.97K+19.2%
Q2 FY2021CQ4 2020Nov 30, 2020$616.56K+52.3%
Q1 FY2021CQ3 2020Aug 31, 2020$711.51K+92.1%
Q4 FY2020CQ2 2020May 31, 2020$683.97K+67.3%
Q3 FY2020CQ1 2020Feb 29, 2020$473.28K-4.8%
Q2 FY2020CQ4 2019Nov 30, 2019$404.85K+6.1%
Q1 FY2020CQ3 2019Aug 31, 2019$370.47K-5.4%
Q4 FY2019CQ2 2019May 31, 2019$408.81K-15.5%
Q3 FY2019CQ1 2019Feb 28, 2019$497.10K+40.6%
Q2 FY2019CQ4 2018Nov 30, 2018$381.41K+40.0%
Q1 FY2019CQ3 2018Aug 31, 2018$391.78K+35.8%
Q4 FY2018CQ2 2018May 31, 2018$483.79K+38.7%
Q3 FY2018CQ1 2018Feb 28, 2018$353.56K+37.7%
Q2 FY2018CQ4 2017Nov 30, 2017$272.44K-9.5%
Q1 FY2018CQ3 2017Aug 31, 2017$288.59K–
Q4 FY2017CQ2 2017May 31, 2017$348.71K–
Q3 FY2017CQ1 2017Feb 28, 2017$256.72K–
Q2 FY2017CQ4 2016Nov 30, 2016$300.96K–

More Biomerica figures

See a number that looks wrong?